Genprex, Inc. financial data

Symbol
GNPX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1601 Trinity Street, Bldg. B, Suite 3.322, Austin, TX
State of incorporation
Texas
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 249 % -56.6%
Debt-to-equity 6.21 %
Return On Equity -319 % -114%
Return On Assets -225 % -77.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.59M shares -95.6%
Common Stock, Shares, Outstanding 2.56M shares -95.1%
Entity Public Float 48.5M USD -26.5%
Common Stock, Value, Issued 2.56K USD -95.1%
Weighted Average Number of Shares Outstanding, Basic 2.16M shares +66.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 13.3M USD -16.2%
General and Administrative Expense 13M USD -8.43%
Costs and Expenses 26.3M USD -12.5%
Operating Income (Loss) -26.3M USD +12.5%
Net Income (Loss) Attributable to Parent -26.1M USD +12.4%
Earnings Per Share, Basic -15.7 USD/shares +52.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.46M USD -75.3%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 4.39M USD -64.5%
Property, Plant and Equipment, Net 1.74K USD -88.6%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Other Assets, Noncurrent 2.21M USD -37.4%
Assets 6.6M USD -58.5%
Liabilities, Current 2.26M USD -41.5%
Liabilities 2.46M USD
Retained Earnings (Accumulated Deficit) -146M USD -21.8%
Stockholders' Equity Attributable to Parent 4.35M USD -63.9%
Liabilities and Equity 6.6M USD -58.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.3M USD +23.6%
Net Cash Provided by (Used in) Financing Activities 6.79M USD +66.5%
Net Cash Provided by (Used in) Investing Activities -15.8K USD +19.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 1.92M shares -96.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.48M USD
Deferred Tax Assets, Valuation Allowance 23.4M USD +36.8%
Deferred Tax Assets, Gross 24.1M USD +34.9%
Depreciation 12.1K USD -39.9%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 16.9M USD +16.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 150M USD +14%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%